Clinical Trials Directory

Trials / Completed

CompletedNCT05517512

Relation Between Protein 13 and Gestational Hypertensive Disorder

Low Serum Pregnancy Protein 13 Early in Pregnancy Might Predict the Oncoming Gestational Hypertensive Disorders, Especially Early-onset Preeclampsia

Status
Completed
Phase
Study type
Observational
Enrollment
138 (actual)
Sponsor
Benha University · Academic / Other
Sex
Female
Age
21 Years – 33 Years
Healthy volunteers

Summary

the attendants of the clinic with a one-missed period (T0) underwent determination of baseline blood pressure (BP) measures and gave blood samples for estimation of levels of placental growth factor (PLGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and pregnancy protein 13 (PP13). The same evaluation was repeated on the 6th, 24th, 32nd, and 36th gestational week (GW). Twenty non-pregnant women gave samples as a negative control group.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTEstimation of Protein 13Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000) 1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20). 2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21). 3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22).

Timeline

Start date
2020-03-12
Primary completion
2021-03-14
Completion
2022-03-19
First posted
2022-08-26
Last updated
2022-08-26

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05517512. Inclusion in this directory is not an endorsement.